Introduction
Choosing an appropriate Good Manufacturing Practice (GMP) manufacturing partner for custom peptide synthesis services requires a detailed assessment of regulatory compliance, analytical expertise, quality management systems, and manufacturing capacity. These factors are essential for ensuring product safety, structural identity, consistent quality, and clinical efficacy. Working with reliable Custom Peptide Synthesis Services enables complex therapeutic peptides to progress efficiently from early discovery and development programs into Phase I-III clinical trials and, ultimately, commercial distribution.
Learn more about Peptide Drug Development CDMO Services.
The contemporary peptide drug development environment includes a broad and increasingly complex range of chemical structures, such as long-chain linear peptides, cyclic sequences, lipopeptides, peptide-drug conjugates (PDCs), and molecules incorporating unnatural or sterically hindered amino acids. Such structural and chemical complexity can create substantial challenges during both synthesis and analytical characterization. Common difficulties include aggregation propensity, racemization during coupling, oxidation of sensitive residues, and challenging purification profiles. Therefore, selecting a Contract Development and Manufacturing Organization (CDMO) involves considerably more than comparing production costs, manufacturing timelines, and anticipated yields. Pharmaceutical developers should conduct a systematic assessment of the CDMO’s Current Good Manufacturing Practice (cGMP) infrastructure, analytical validation practices, data integrity systems, and previous regulatory inspection history. Choosing a manufacturing vendor without adequate qualifications can expose a pharmaceutical development program to serious risks, including failed release testing, unexpected clinical toxicity associated with insufficiently characterized impurities, regulatory clinical holds, and substantial losses of development capital.
Explore our guide on How to Choose a Peptide CDMO in the US.
Share via:
Quick Summary:
- Selecting the right GMP CDMO for custom peptide synthesis requires evaluating regulatory compliance, quality systems, analytical capabilities, manufacturing capacity, and inspection history—not just cost and timelines.
- Regulatory compliance should align with key FDA and ICH requirements, including 21 CFR 210/211/600, ICH Q7, Q6B, Q1A(R2), Q9, and Q10, ensuring consistent quality, safety, purity, and stability.
- Phase-appropriate GMP should evolve with development: research-grade synthesis may support preclinical work, while Phase I requires stronger traceability and release testing, and Phase III/commercial manufacturing requires validated processes, CPP/CQA control, and long-term stability programs.
- Comprehensive analytical characterization is essential for peptide identity, purity, structure, and impurities using techniques such as HRMS, MALDI-TOF, RP-HPLC/UHPLC, LC-MS/MS, CD, and NMR, along with endotoxin, residual solvent, elemental impurity, sterility, and degradation testing.
- CDMO facility and quality evaluation should include classified cleanrooms, environmental monitoring, qualified equipment (IQ/OQ/PQ), validated cleaning, ALCOA+ data integrity, 21 CFR Part 11 compliance, deviation/OOS investigations, CAPA, and change control.
- Manufacturing scalability and process validation require suitable SPPS, LPPS, or hybrid technologies, identification of critical process parameters, and demonstrated control of critical quality attributes during scale-up from development to commercial production.
- GMP offers stronger control than non-GMP manufacturing, including tighter contamination and dosing controls, greater documentation, and stronger regulatory readiness; a structured CDMO audit checklist covering regulatory history, QMS, analytics, facilities, data integrity, raw materials, stability, and scalability helps minimize development and regulatory risks.
Regulatory Compliance and Quality Frameworks in Custom Peptide Synthesis Services
A competent GMP manufacturing partner providing custom peptide synthesis services should demonstrate documented compliance with internationally recognized regulatory requirements, including US Food and Drug Administration (FDA) regulations and International Council for Harmonisation (ICH) quality guidelines. These regulatory frameworks establish stringent expectations for facility operations, equipment qualification, analytical testing, documentation, and batch release processes, thereby supporting consistent product safety, quality, and potency.
Read our overview on Outsourcing Peptide Manufacturing to a CDMO.
Key FDA Regulations and ICH Quality Guidelines
Important regulatory frameworks applicable to peptide manufacturing include FDA 21 CFR Parts 210, 211, and 600, together with ICH Q7, Q6B, Q1A(R2), and Q3A/B guidelines. Collectively, these standards establish expectations for raw material qualification, analytical method validation, impurity control, acceptance criteria, and real-time product stability.
Adherence to these regulatory requirements helps ensure that active pharmaceutical ingredients (APIs) consistently satisfy predefined and reproducible quality parameters:
- FDA 21 CFR Part 210 & 211: Establishes the statutory foundation for cGMP requirements applicable to the manufacturing, processing, packing, or holding of finished pharmaceuticals and APIs.
- FDA 21 CFR Part 600: Establishes requirements for biological product standards, including expectations related to safety, purity, and potency for large peptides and therapeutic proteins.
- ICH Q7 Guidance: Provides internationally applicable Good Manufacturing Practice requirements specifically intended for Active Pharmaceutical Ingredients, covering areas such as facility design, material management, equipment, and batch execution.
- ICH Q6B Specifications: Establishes test procedures and acceptance criteria for biotechnological and biological products and requires detailed characterization of physicochemical properties, immunochemical characteristics, and biological activity.
- ICH Q1A(R2) Stability Testing: Defines protocols for long-term, intermediate, and accelerated stability studies used to establish product shelf-life and appropriate storage conditions.
- ICH Q9 & Q10 Quality Systems: Provide frameworks for Quality Risk Management and Pharmaceutical Quality Systems, supporting consistent operational control throughout the pharmaceutical product lifecycle.
Phase-Appropriate GMP Implementation Across Clinical Stages
Phase-appropriate GMP implementation allows the level of quality control and manufacturing oversight to increase as a peptide development program advances through successive clinical stages. This approach moves from flexible development controls during preclinical research toward comprehensive validated manufacturing systems required for commercial production. Aligning GMP requirements with the development phase helps optimize the use of development resources while maintaining appropriate clinical safety, product quality, and batch traceability.
During preclinical research and lead optimization, non-GMP or controlled research-grade synthesis may be adequate for evaluating target binding, biological activity, and preliminary pharmacokinetic profiles. However, when a peptide candidate progresses toward Phase I First-in-Human (FIH) clinical trials, phase-appropriate cGMP requirements become increasingly important. At this point, the quality system should provide comprehensive raw material traceability, validated identity and purity release testing, appropriate bioburden and endotoxin limits, and initial stability monitoring under applicable ICH conditions.
When a peptide drug candidate reaches Phase III clinical trials and approaches commercial registration, comprehensive cGMP process validation becomes necessary. This includes establishing Critical Process Parameters (CPPs), performing commercial-scale process validation batches, completing full analytical method validation under ICH Q2(R1), and implementing long-term stability programs covering relevant climatic zones. The appropriate GMP strategy is also influenced by product classification and manufacturing requirements. For example, personalized neoantigen peptide vaccines require flexible, small-scale GMP manufacturing platforms that can support rapid production and individual batch release. In contrast, large-volume metabolic therapies, including GLP-1 receptor agonists, require industrial-scale manufacturing platforms with stringent cGMP controls implemented from the early stages of development.
Discover our specialized GLP-1 Peptide Analytical Characterization Services.
Technical and Analytical Characterization for Custom Peptide Synthesis Services
Comprehensive analytical characterization associated with custom peptide synthesis services requires the use of multi-attribute testing platforms to verify sequence identity, determine chromatographic purity, assess secondary structures, and identify and characterize degradation products. Implementing validated analytical procedures is essential for reducing the likelihood of batch release failures and for generating appropriate data to support Investigational New Drug (IND) applications and other regulatory submissions.
Review detailed insights on Peptide Analytical Characterization Services.
Purity, Identity, and Structural Confirmation Testing
Peptide sequence identity and structural purity can be established using High-Resolution Mass Spectrometry (HRMS), MALDI-TOF mass spectrometry, and Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC). Additional structural characterization techniques, including circular dichroism and nuclear magnetic resonance (NMR) spectroscopy, can provide further information regarding peptide secondary and tertiary conformations.
Verification of molecular weight and primary amino acid sequence for a custom synthetic peptide requires high-resolution mass spectrometry (HRMS) approaches, including Electrospray Ionization (ESI-MS) and Matrix-Assisted Laser Desorption/Ionization Time-of-Flight (MALDI-TOF). These mass spectrometric techniques allow the experimentally determined monoisotopic mass to be compared with the theoretical molecular mass, providing confirmation of molecular identity within established mass accuracy tolerances.
Chromatographic purity is generally established using validated RP-HPLC or Ultra-High Performance Liquid Chromatography (UHPLC) procedures. RP-HPLC separates the desired peptide API from closely related product-related impurities, including deletion sequences lacking individual amino acid residues, truncated peptide fragments, and racemized diastereomers. Depending on the intended dose, therapeutic window, and product characteristics, clinical applications may require chromatographic purity specifications ranging from ≥ 95.0% to ≥ 98.0%. For structurally complex cyclic peptides or disulfide-bonded peptides, analytical characterization must extend beyond primary molecular mass confirmation. Techniques such as Circular Dichroism (CD), 2D Nuclear Magnetic Resonance (NMR) spectroscopy, and enzymatic peptide mapping can be applied to demonstrate the appropriate secondary structure and verify correct disulfide linkage patterns.
Examine our Peptide Characterization Case Study of Semaglutide.
Impurity Profiling and Contaminant Screening
Impurity profiling evaluates product-related substances, including deletion fragments, oxidation species, and diastereomers, whereas contaminant screening evaluates potential contaminants such as bacterial endotoxins, bioburden, residual organic solvents, and heavy metals. Effective control of both process-related and product-related impurities is important for minimizing the potential for adverse immunogenic responses and cellular toxicity in clinical populations.
Analytical characterization performed for GMP batch release generally incorporates a broad panel of specialized tests, as summarized below:
| Core Analytical Parameter | Primary Testing Methodology | Regulatory Guidance Reference | Standard Release Specification |
|---|---|---|---|
| Molecular Identity & Mass | HRMS (ESI-MS / MALDI-TOF) | ICH Q6B | Monoisotopic mass matches theoretical value within ± 0.01 Da |
| Chromatographic Purity | RP-HPLC / UHPLC | ICH Q6B / USP | Typically ≥ 95.0% to ≥ 98.0% main peak area |
| Product Impurity Profile | LC-MS/MS & RP-HPLC | ICH Q3A/B | Specified individual impurities < 0.5%; total impurities < 2.0% |
| Bacterial Endotoxins | Limulus Amebocyte Lysate (LAL) | USP | < 5.0 EU/mg (adjusted for therapeutic dose) |
| Residual Organic Solvents | Headspace GC-MS / GC-FID | USP / ICH Q3C | Compliant with ICH Class 1, Class 2, and Class 3 limits |
| Elemental Impurities | ICP-MS | USP / ICH Q3D | Below Permitted Daily Exposure (PDE) thresholds |
| Bioburden / Sterility | Direct Inoculation / Membrane Filtration | USP | Compliant with parenteral safety specifications |
| Forced Degradation Profile | Stress Testing (Heat, Light, pH, Oxidation) | ICH Q1A(R2) | Identification of primary degradation pathways |
Critical Evaluation Criteria for Choosing Custom Peptide Synthesis Services
Assessing a contract development and manufacturing organization (CDMO) for custom peptide synthesis services requires careful examination of cleanroom environmental controls, equipment qualification procedures, quality management systems, and manufacturing capacity that can support scale-up. A detailed operational assessment helps ensure effective technology transfer, reproducible manufacturing performance, and uninterrupted clinical supply.
Learn about Peptide CDMO Scale-Up Services.
Cleanroom Infrastructure, Environmental Controls, and Equipment Qualification
GMP manufacturing facilities should operate classified cleanrooms with appropriate positive pressure differentials, continuous control of temperature and humidity, and qualified equipment managed through strict IQ/OQ/PQ protocols. Proper environmental controls are essential for minimizing bioburden risks and reducing the possibility of hygroscopic or oxidative degradation of peptide products.
Peptide active pharmaceutical ingredients intended for clinical administration must undergo synthesis, purification, and isolation within appropriately controlled cleanroom environments. Facility layouts should provide suitable separation between synthesis activities, preparative chromatography, lyophilization, and bulk packaging operations to minimize cross-contamination risks. Environmental monitoring programs should continuously evaluate airborne particulate concentrations, surface microbial contamination, and personnel airlock conditions. Cleanroom HVAC systems should maintain positive pressure in relation to adjacent non-classified areas while controlling ambient temperatures between 15°C and 25°C and maintaining relative humidity below 60% to limit microbial growth and reduce moisture uptake by hygroscopic lyophilizates.
All manufacturing and analytical equipment, including automated solid-phase synthesizers, preparative HPLC skids, industrial lyophilizers, and analytical chromatography instruments, should undergo formal qualification before routine use. Equipment qualification includes Installation Qualification (IQ), which confirms that equipment has been installed correctly; Operational Qualification (OQ), which verifies that equipment operates appropriately across defined operating ranges; and Performance Qualification (PQ), which demonstrates consistent performance under routine manufacturing conditions. Validated cleaning procedures must also be established to confirm effective removal of residual peptides, organic synthesis solvents such as DMF or NMP, and cleavage reagents such as TFA between production campaigns.
Quality Assurance, Data Integrity, and Change Control
Quality assurance for peptide manufacturing depends on robust ALCOA+ data integrity principles, computerized systems compliant with 21 CFR Part 11, and well-established CAPA processes. Together, these quality controls support complete batch record traceability, protection of electronic audit trails, and systematic assessment of manufacturing and analytical changes.
A mature Quality Management System (QMS) establishes comprehensive data integrity requirements across electronic and manual documentation systems. Data integrity procedures should follow ALCOA+ principles, ensuring that information generated during synthesis and testing remains Attributable, Legible, Contemporaneously recorded, Original, and Accurate. Electronic systems involved in manufacturing or analytical testing, including chromatography data software (CDS) and automated synthesizer controllers, should comply with FDA 21 CFR Part 11. Such compliance requires controlled user access, appropriate separation of administrative responsibilities, secure audit trails that capture original information and subsequent changes, and routinely validated data backup procedures.
Quality assurance departments should additionally maintain effective deviation management procedures, Out-of-Specification (OOS) investigation processes, and Corrective and Preventive Action (CAPA) systems. Any deviation from an approved batch execution procedure or unexpected analytical result should initiate a formal investigation to determine the root cause before the affected lot can proceed to QA release. Robust change control systems are also essential to ensure that proposed modifications involving raw material suppliers, reaction conditions, purification column media, or analytical procedures are formally evaluated for their potential effects on product quality before implementation.
Synthesis Scalability and Process Validation
Scalable custom peptide synthesis services may employ solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), or hybrid technological approaches that can transition from benchtop development activities to commercial multi-kilogram manufacturing. Establishing Critical Process Parameters (CPPs) during process development is essential for maintaining consistent Critical Quality Attributes (CQAs) as manufacturing scale increases.
Selecting a manufacturing partner with diverse synthetic technology capabilities is particularly important when peptide programs involve different sequence lengths and production quantities. Solid-Phase Peptide Synthesis (SPPS) remains the gold standard for linear peptides up to 40-50 amino acids because it provides efficient coupling cycles and supports automated synthesis. Liquid-Phase Peptide Synthesis (LPPS) and hybrid SPPS/LPPS convergent fragment strategies can be advantageous for longer peptide sequences and high-volume commercial products, including large-scale metabolic peptide manufacturing.
Explore options for Peptide API Scale-Up Services.
Process validation involves identifying Critical Process Parameters (CPPs), including amino acid coupling times, deprotection reagent concentrations, cleavage temperatures, and preparative HPLC fraction collection criteria, and establishing their relationships with Critical Quality Attributes (CQAs), such as chemical purity, residual solvent levels, and biological potency. Demonstrating reproducible process control during scale-up is essential to ensure that moving from a 10-liter SPPS reactor to a 500-liter industrial system maintains consistent peptide quality and does not introduce unexpected aggregation, impurity formation, or yield loss.
Comparing GMP vs Non-GMP Custom Peptide Synthesis Services
A comparison of GMP vs non-GMP custom peptide synthesis services highlights substantial differences in regulatory oversight, environmental controls, analytical testing requirements, and documentation standards. Although non-GMP materials can be appropriate for early discovery and target evaluation, cGMP compliance becomes essential when peptide products are intended for human clinical studies and commercial distribution.
Compare operational choices in our breakdown of Peptide CDMO vs CMO.
Understanding the operational and economic differences between GMP and non-GMP manufacturing, which is frequently designated as Not-for-GMP or NGMP, allows biopharmaceutical companies to select an appropriate manufacturing grade for each stage of product development:
- Financial Investment: cGMP peptide manufacturing generally involves costs 40% to 60% higher than non-GMP synthesis. The increased cost is associated with controlled cleanroom operations, continuous environmental monitoring, extensive analytical validation, comprehensive documentation, and dedicated QA review and release activities.
- Contamination Rates: Comparative industry surveys have reported contamination rates of approximately 12% to 18% for non-GMP research peptides, with contamination potentially arising from residual synthesis reagents, cross-contamination, or inadequately monitored microbial bioburden. In comparison, cGMP-manufactured peptide APIs can achieve contamination rates below 0.1% through the use of validated cleanrooms, qualified equipment, and stringent raw material testing procedures.
- Dosing Accuracy: cGMP peptide manufacturing supports strict dosing accuracy within ± 5% of target concentrations, whereas non-GMP peptides may demonstrate potency variations of 25% to 50% because of unvalidated filling procedures, variable counterion content, and unquantified water content.
- Documentation Rigor: Non-GMP peptide orders generally provide a standard Certificate of Analysis (COA) containing information such as HPLC purity and mass spectrometry peaks. In contrast, cGMP batch release typically includes a comprehensive Master Batch Record (MBR), complete raw analytical data packages, stability protocol records, chain-of-custody documentation, and formal QA release certification.
- Facility Workflow Separation: Multi-purpose facilities supporting both research and clinical manufacturing must implement effective workflow separation between GMP and NGMP activities. This separation can require clearly identified equipment, dedicated solvent lines, independent HVAC zones, and segregated raw material storage areas to protect clinical supply chains from cross-contamination.
Evaluate strategic partners using our guide to Canadian vs US Peptide CDMOs.
Comprehensive CDMO Audit Checklist
A comprehensive CDMO audit checklist offers a systematic method for assessing a potential manufacturing partner’s regulatory compliance, quality infrastructure, analytical capabilities, and facility preparedness before entering into a manufacturing agreement. Thorough facility audits can identify operational weaknesses, reduce manufacturing and regulatory risks, and protect investments made throughout drug development.
The following matrix presents major audit categories, specific evaluation criteria, applicable regulatory standards, and practical approaches for verifying the capabilities of prospective CDMO partners:
| Audit Category | Specific Evaluation Criterion | Regulatory Standard | Verification Approach |
|---|---|---|---|
| Regulatory History | Historical FDA/EMA inspection reports, Form 483s, and warning letter history | 21 CFR Part 210 / 211 | Review regulatory audit summaries, inspection observations, and closeout letters. |
| Quality System (QMS) | Operational maturity of deviation handling, OOS investigations, and CAPA systems | ICH Q10 Guidance | Audit deviation logs, root-cause analysis files, and CAPA resolution timelines. |
| Analytical Validation | Validated method portfolios for RP-HPLC, HRMS, residual solvents, and endotoxins | ICH Q2(R1) / USP | Inspect analytical validation packages, instrument calibration records, and IQ/OQ/PQ logs. |
| Cleanrooms & HVAC | Classified cleanroom environmental controls (15-25°C, <60% RH, positive pressure) | cGMP Cleanroom Standards | Review continuous environmental monitoring logs, HEPA filtration records, and pressure logs. |
| Data Integrity | 21 CFR Part 11 software compliance, ALCOA+ controls, and audit trail security | FDA Data Integrity Guidance | Audit software access permissions, electronic audit trails, and automated backup procedures. |
| Raw Material Control | Qualified supplier lists, raw material identity testing, and vendor audit programs | ICH Q7 Section 7 | Inspect vendor qualification procedures, incoming testing logs, and storage conditions. |
| Stability Testing | ICH climatic zone-mapped stability chambers with environmental backup systems | ICH Q1A(R2) Guideline | Audit stability chamber calibration logs, temperature alarm logs, and backup power generators. |
| Process Scalability | SPPS/LPPS capacity, preparative HPLC column scale, and lyophilization capacity | Process Validation Standards | Assess synthesizer vessel volumes, column dimensions, and historical batch scale-up data. |
Compare options with our guide on Peptide CDMO vs CRO Capabilities.
Conclusion
Selecting an appropriate GMP manufacturing partner for custom peptide synthesis services requires a comprehensive assessment of regulatory compliance history, analytical capabilities, cleanroom infrastructure, quality systems, and process scalability. Engaging dependable Custom Peptide Synthesis Services can help biopharmaceutical organizations reduce regulatory risks, support efficient clinical development timelines, and manufacture high-purity therapeutic peptides suitable for clinical and commercial applications.
A suitably qualified CDMO functions as more than a manufacturing supplier; it can serve as a strategic development partner capable of addressing complex chemical challenges and generating robust analytical data packages that support global regulatory submissions. To discuss custom peptide synthesis requirements, obtain support for analytical method development, or evaluate phase-appropriate cGMP manufacturing platforms, contact the technical expert team through the ResolveMass Laboratories Contact Page.
Frequently Asked Questions
GMP peptide synthesis is generally required when a peptide is being prepared for administration to human subjects, particularly before Phase I First-in-Human (FIH) clinical studies. Research-grade material may be appropriate during discovery and preclinical development, but phase-appropriate cGMP controls must be established as the candidate progresses toward IND submission and clinical evaluation.
GMP peptide active pharmaceutical ingredients are subject to several regulatory frameworks, including FDA 21 CFR Parts 210, 211, and 600, ICH Q7, and ICH Q6B. Additional requirements may apply through ICH Q1A(R2) for stability testing, ICH Q3A/B for impurity assessment, and ICH Q2(R1) for analytical method validation.
Peptide purity is commonly assessed through Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), which separates the desired peptide from related substances and determines the proportion represented by the main peak. For clinical applications, typical chromatographic purity specifications may range from ≥ 95.0% to ≥ 98.0%, depending on the product’s characteristics, intended dose, potency, and therapeutic safety requirements.
High-Resolution Mass Spectrometry (HRMS) and MALDI-TOF mass spectrometry are widely used to verify peptide molecular mass and establish molecular identity. Additional approaches, including tandem mass spectrometry (MS/MS), amino acid analysis (AAA), and enzymatic peptide mapping, can provide further confirmation of sequence order, structural features, and sequence-related modifications.
Impurity profiling is essential for detecting and characterizing product-related substances such as deletion sequences, truncated fragments, oxidation products, and stereoisomers. Comprehensive identification and control of these impurities help minimize potential safety concerns, including immunogenicity and unexpected toxicity, while ensuring that the peptide API remains within established regulatory acceptance criteria.
GMP peptide stability programs under ICH Q1A(R2) evaluate product behavior under long-term, intermediate, and accelerated storage conditions. Typical conditions include 5°C ± 3°C for long-term testing, 25°C ± 2°C / 60% RH for intermediate testing, and 40°C ± 2°C / 75% RH for accelerated testing, alongside forced degradation studies involving heat, light, oxidation, and pH stress.
Cleanroom controls help protect peptide manufacturing operations by limiting airborne particulates, microbial contamination, and environmental variability. HEPA filtration, positive pressure systems, and continuous temperature and humidity monitoring support controlled manufacturing conditions, while maintaining temperatures between 15°C and 25°C and relative humidity below 60% can help protect sensitive peptide materials from moisture-related and degradation-related risks.
Data integrity is fundamental to ensuring that manufacturing records, analytical results, electronic audit trails, and quality documentation remain accurate, complete, traceable, and reliable. Compliance with ALCOA+ principles and 21 CFR Part 11 helps protect electronic records from unauthorized alteration and provides regulatory authorities with confidence in the authenticity and reliability of submitted manufacturing and analytical data.
GMP peptides generally have higher manufacturing costs because their production requires extensive quality and regulatory controls beyond those used for research-grade materials. Expenses can include classified cleanroom operations, environmental monitoring, equipment qualification, analytical method validation, comprehensive documentation, batch review, and dedicated QA oversight, with GMP synthesis potentially costing 40% to 60% more than non-GMP production.
Reference:
- Elsayed, Y. Y., Kühl, T., & Imhof, D. (2025). Regulatory guidelines for the analysis of therapeutic peptides and proteins. Journal of Peptide Science, 31(3), e70001. https://doi.org/10.1002/psc.70001
- U.S. Food and Drug Administration. (2023, May). Current good manufacturing practice (CGMP) regulations. https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). Quality guidelines. https://www.ich.org/page/quality-guidelines
- U.S. Food and Drug Administration. (2018, April). Q7 good manufacturing practice guidance for active pharmaceutical ingredients: Questions and answers—Guidance for industry. https://www.fda.gov/media/112426/download
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1999). Specifications: Test procedures and acceptance criteria for new drug substances and new drug products: Chemical substances (ICH Q6A). https://database.ich.org/sites/default/files/Q6A%20Guideline.pdf
Get In Touch With Us
About The Author
